

INDIA RESEARCH

**AGRI-INPUTS** 

MANAGEMENT MEETING NOTE

BSF SENSEX: 16167

28 NOVEMBER 2011

#### **UNRATED**

# PI Industries

At a tipping point!

Rs480

Mkt Cap: Rs12bn; US\$230m

We met the management of PI Industries (PI) for an update on the business. PI is a differentiated model in the Indian agrochemical space – unlike most peers, which focus on supplying off-patent agro-chemicals, PI participates in the "innovation" value chain; e.g., custom synthesis and selling in-licensed formulations in the domestic market. After a long gestation, PI's investments in its two-pronged business model have begun paying off as reflected in 25% revenue CAGR with 57% EBITDA CAGR over FY08-11. With ~\$55m revenues in FY11 and a current order book of ~\$325m (primarily comprising on-patent products), PI's contract manufacturing business is at a tipping point. The company's ~\$100m domestic formulations business will be driven by the launch of innovative products in-licensed from global players as it leverages the opportunity provided by the implementation of the products patent regime in India. Business momentum is set to accelerate, with the management targeting >30% CAGR in revenues over FY11-13 and ~200bp growth in EBITDA margins. We estimate 37% earnings CAGR over FY11-13. At Rs480/ share, the stock trades at 13.5x FY12E and 9.9x FY13E earnings. With a highly scalable model and strong growth visibility, PI is clearly one of the companies to watch out for in the agri-inputs space.

Exhibit 1: Key financials


As on 31 March	FY08	FY09	FY10	FY11	FY12E	FY13E
Net sales (Rs m)	3,709	4,629	5,425	7,202	9,183	11,478
Adj. net profit (Rs m)	64	242	417	650	888	1,218
Shares in issue (m)	14	14	22	22	25	25
Adj. EPS (Rs)	4.5	17.1	19.3	29.3	35.5	48.7
% growth	47.7	279.1	12.8	52.0	21.3	37.1
PER (x)	106.5	28.1	24.9	16.4	13.5	9.9
Price/Book (x)	9.7	7.2	7.8	5.2	3.9	2.8
EV/EBITDA (x)	26.9	13.6	13.8	10.6	8.5	6.4
RoE (%)	9.5	29.5	36.6	38.3	34.5	33.3
RoCE (%)	8.6	17.9	22.5	25.8	26.9	30.1

Source: Company, IDFC Securities Research

# Unique business model; strong focus on innovation

Incorporated in 1947, PI Industries has built a strong and unique business with two focused segments, namely agriinputs and custom synthesis. Unlike peers (United Phosphorus, Rallis, etc.) who focus on manufacturing and distributing off-patent molecules in the domestic and export markets, PI focuses on partnering with global agrochemical players in the proprietary segment of the agro-chemicals market. As part of this strategy, PI concentrates on selling novel in-licensed agrochemical products from MNCs in the domestic market and partners with MNCs to provide custom synthesis services primarily for their on-patent agrochemical products. It does not export off-patent agrochemical products, which has traditionally been the primary growth driver for peers like United Phosphorus.

Exhibit 2: Balanced mix of agri-input and custom synthesis business




Source: Company, IDFC Securities Research

## After a long gestation, differentiated model beginning to deliver

PI's adoption of an unconventional business strategy focused on partnering with MNCs involved a fairly long gestation period as it assiduously worked on securing and strengthening key client relationships in the custom synthesis business as well as on selection/ launch of innovative agrochemical products in the Indian market. This strained its financials in the interim as revenue/ profitability pick-up lagged investments in the two segments. However, PI's strong financial performance over FY08-11 (25% revenue CAGR and 117% PAT CAGR) underlines the success of its strategy.

Exhibit 3: Business momentum has picked-up since FY09 despite macro economic slowdown



Source: Company, IDFC Securities Research

Over FY08-11, PI's agri-input and CRAMS businesses grew by 21% and 50% CAGR and have firmly established the company as one of the leading agrochemical players in the Indian industry. In FY11, PI recorded revenues of Rs7.2bn, with the domestic agrochemicals and custom synthesis segments contributing 62% and 34% respectively. With a critical mass in place across both business segments, the management expects to maintain the high growth trajectory in the near to medium term.


### Growing focus of global MNCs on innovation and higher R&D bode well for PI

While off-patent products have been gaining market share in the past 6-8 years (>9%), the proprietary ones have seen renewed focus by companies in the past few years. With proprietary products registering higher growth rates, most global players like Bayer, Syngenta, etc, have increased focus on launching new products and indicated an increase in R&D expenditure over the next few years. For example, Syngenta's revenues from new products have grown at a CAGR of 47% in the past six years. Similarly, Bayer, one of the world's leading innovative agchem companies, has indicated >20% annual increase in R&D expenditure by 2015 to >Eur850m. Innovation is fast becoming a significant part of companies' core business models for sustainable future growth.


According to consultancy firm Phillips McDougall, investment in R&D by the agchem industry to expected to grow from \$2.3bn now to \$3bn by 2012. While a part of the increase is attributable to the rising cost of discovery and development (+39%; \$184m in 2000 to \$256m during 2005-08), higher probability of products reaching the market (unlike in the pharmaceutical industry where many products fail during clinical trials) has encouraged companies to increase their R&D spending.

Exhibit 4: Industry snapshot - strong growth ahead for agchem industry


#### Innovation becoming part of core business model




# Proprietary products witnessing renewed interest



#### Syngenta's growth driven by new product launches



#### Bayer raised its R&D spending to >€50m annually by 2015



Source: Company presentations, IDFC Securities Research

## Agri-inputs business: Launch of in-licensed products to drive growth

PI is among the leading and oldest players in the domestic agri-input industry; it primarily deals in agro-chemicals, specialty fertilizers and plant nutrients. Leveraging on its strong brand among farmers built over more than 50 years, a vast marketing & distribution network in rural India (35000+ strong retailer base), and strong business processes, PI has established itself as one of the top 5 agrochemical companies in India.

PI currently markets  $\sim$ 22 products in the domestic market (including 5-6 in-licensed / co-marketed products). This is a significantly smaller product basket compared to most peers which offer a significantly diversified basket of off-patent products. The company is the market leader in most of its products, including  $\sim$ 10 off-patent products, which is reflective of the quality of its business. The key marketed products include Nominee Gold (rice herbicide), Foratox (insecticide), Roket (insecticide) and Biovita (plant nutrient).

Over FY06-11, revenues have grown at a CAGR of 21% driven by strong response to new product launches (especially Nominee Gold) as well as steady growth of off-patent products.




Exhibit 5: Agri-input business has grown by 21% CAGR over FY06-11

Source: Company, IDFC Securities Research

#### In-licensing of innovator products – key growth strategy

- Pl's domestic market strategy is based on steering clear of me-too products and focusing on launching innovative agri-chemical products that have significant scale-up potential and limited competition. Given the relatively lax IP protection laws prevailing in the country (until the adoption the WTO TRIPS agreement in 2005, which recognized product patents), MNCs (particularly the small- to mid-size ones) had been largely reluctant in launching innovative products in the Indian market. The gradual implementation of the patent regime will provide an incentive to MNCs to launch their newer products in the market as they will be able to ward off generic competition during exclusivity.
- PI has sought to leverage the post-2005 scenario by partnering with small- to mid-size MNCs to get exclusive
  marketing rights to launch their innovative products in the Indian market. The company's extensive distribution
  network in rural India makes a strong partnering candidate for MNCs such in-licensing deals. PI has already secured
  exclusive marketing rights for about five such products and is constantly evaluating prospects to expand its product
  portfolio.
- The success of Nominee Gold, an in-licensed novel rice herbicide, launched in FY10 is a strong indicator of the
  potential of this strategy. The product received a tremendous response from farmers and was also recommended

by many state universities. In FY11, it became one of the fastest growing herbicides in the country. PI expects Nominee Gold to become the largest herbicide brand in India.

• PI has filed for registration of three new molecules, which are expected to be commercially launched by FY13. Overall, it has a pipeline of 7-8 new products to be launched over the next 3-4 years through the in-licensing route.

Given the favourable growth dynamics of the domestic agrochemical market, driven by strong commodity prices, and its robust portfolio comprising existing as well as newly in-licensed products, PI expects the agri-inputs business to grow by >30% CAGR over the next two years.

## Custom synthesis business (CRAMS): Preferred partner for global MNCs

After more than a decade of perseverance, PI has established itself as a leader in custom synthesis of agchem and specialty products (APIs and late-stage intermediates) in India. We believe PI has been among the earliest entrants in the space and its efforts to build relationships with global innovators by leveraging its strong capabilities in complex chemistry have finally begun to pay off. PI has established strong relationships with most leading agrochemical companies in the world, but particularly in Japan and the EU.

PI is already supplying 11-12 "recently commercialized" agrochemical products to these companies. Further, the company has indicated that another 25-30 products are at different stages of development and will be launched over the next few years. PI expects that each of these products would generate >\$10m annual revenues at their peak.

In our view, given the long development cycles of the custom synthesis business, it takes at least 3-4 years before the investments begin to bear fruit.

Work-flow Typical value addition process timeline Customer enquiry Process & cost review Pre-feasibility study Sample validation 3<sup>rd</sup> Commercial Sign secrecy Order (200 MT) 1st sample SOP & plant design 1st Commercial (Supply up to agreement Order (5MT) Mar-12) customer Customer Process evaluation approval/agreement Mar-10 Aug-10 Apr-11 Feb-10 Jun-10 Nov-10 Bench scale trials Detailed plant engg. Plant erection & Desktop costina Sample 2<sup>nd</sup> Commercial Signed installing Enquiry approved by Order (57 MT) Agreement of received customer 1500 mt. (Supply up to Mar-11) (\$36m) for 3 yrs Raw material Customer approval procurement Pilot/Kilo lab scale up Commercial production

Exhibit 6: Custom synthesis division – work-flow and value addition process timeline

Source: Company

For PI, after a prolonged investment phase, the custom synthesis business has now reached a tipping point. This is reflected in 50% revenue CAGR in the business over FY08-11 to Rs2.44bn in FY11. PI has an order book of >\$325m (and growing steadily), which provides strong growth visibility for at least the next three years.

As a strategy PI does not focus on manufacturing off-patent products, which enhances the quality of its pipeline. Given that the company only focuses on early-stage molecules, we believe most of its contracts will continue for significant periods (>10 years) and will also progressively grow as "end product" sales scale up. PI will be benefitted by the significantly large lifecyles (agrochemical products typically retain significant market shares for several years even after patent expiry), which are fairly common in the agrochemical industry.

### Key competencies driving growth

- More than 15 years experience and significant investments in building state-of-the-art process research and manufacturing facilities for intermediates and active ingredients
- Strong scientific capabilities; currently has ~100 scientists on its rolls, including 22 PhD holders
- Focus on building process R&D capabilities; one-stop shop for all customer requirements in fine chemicals, ranging from process evaluation, bench-scale trials, kilo lab, pilot plant to commercial manufacturing
- Non-compete and IP-driven business model.

## PI-Sony R&D center – underline PI's strong chemistry capabilities

PI recently set up a partnership with Sony Corporation of Japan to set up a joint R&D center to undertake collaborative research on synthetic organic chemicals for applications in the electronic industry. This tie-up further underlines PI's strong chemistry capabilities which have enabled it to build an industry-best custom synthesis business.

With a fast growing order book and adequate manufacturing capacity, PI expects the CRAMS business to grow by >35% CAGR over the next two years. It is also aiming to leverage its relationships and capabilities to explore custom synthesis opportunities in the pharmaceuticals and imaging chemicals arena. This will provide a further fillip to growth as it opens a significantly larger market opportunity.




Exhibit 7: Custom synthesis division – strong order book provides growth visibility

Source: Company, IDFC Securities Research


## Financials: Business model beginning to deliver

Pl's revenues have grown by >28% CAGR (excluding polymer compounding business) in the past three years. We believe Pl's contract manufacturing business is at a tipping point in its growth trajectory due to its deep relationships with most global agrochemical majors built over the past 15 years,  $\sim$ \$55m revenues in FY11, and a current order book of  $\sim$ \$325m (primarily comprising on-patent products) which is growing steadily. Also, the  $\sim$ \$100m domestic formulations business will be driven by the launch of innovative products in-licensed from global players as it seeks to leverage the opportunity provided by the implementation of the products patent regime in India. While in-licensed and co-marketed products accounted for  $\sim$ 35% of sales in FY11 ( $\sim$ 10% in FY08), PI expects this segment to contribute  $\sim$ 70% to sales over the next 4-5 years along with significantly enhanced profitability.

## Better days ahead...

With both the agri-inputs and CRAMS businesses witnessing strong growth, we believe the momentum will sustain in the coming years. In H1FY12, revenues grew by 43% yoy to Rs4.5bn, which is already 63% of FY11 revenues. The management has guided for revenue CAGR of 30%+ over FY11-13 accompanied by ~200bp improvement in EBITDA margin with enhanced operating leverage. We estimate >37% CAGR in earnings over FY11-13E.

**Exhibit 8: Key financials** 



Source: Company, IDFC Securities Research

#### Focussing on the core: Divestment of polymer division

In April 2011, PI completed the divestment of its polymer compounding division to French specialty chemical MNC Rhodia SA for a consideration of ~Rs730m. Set up in the 1990s, the division (~5% of revenues in FY11) was divested with the objective of concentrating on core business areas of agri-inputs and custom synthesis and investing in these high-growth areas. The polymer business witnessed good growth in FY11, but product margins came under pressure due to high volatility in raw material prices, which could not be passed on to customers.

# Valuations and view


With its differentiated business model, focused on participating in the "innovation" part of the agrochemical industry value chain, having reached a tipping point in terms of growth momentum, the best is ahead for PI. Return ratios should steadily expand with most of the intensive capex behind and significant improvement in operating cash flows. At Rs480/share, the stock currently trades at 13.5x FY12E and 9.9x FY13E earnings. Despite the stock having almost doubled in the past 12 months, driven by a highly scalable model and strong growth visibility, PI is clearly one of the stocks to watch out for in the agri-inputs space.

Exhibit 9: Comparative valuations table

Companies	Price	Mkt cap	Earnings CAGR	P/	E (x)	EV/EB	ITDA (x)	RoE	RoCE
(Rs)	(Rs)	(Rs bn)	FY11-13E (%)	FY12E	FY13E	FY12E	FY13E	(%)	(%)
PI Industries	480	12	37.3	13.5	9.8	8.5	6.2	34.5	26.9
United Phosphorus	130	60	29.5	8.4	6.2	5.3	4.3	17.8	17.9
Rallis India*	152	29	27.0	18.7	14.6	12.1	9.7	27.5	13.8

Source: IDFC Securities Research, \*consensus estimates

Exhibit 9: PI Industries - P/E band chart



Source: Bloomberg


## Company background

Incorporated in 1947, PI Industries focuses on agri-Input and custom synthesis businesses. It has over 1,100 employees. PI was earlier known as Pesticides India and was renamed PI Industries in 1993 to reflect its new diversified businesses. Mr. Mayank Singhal is the Managing Director and CEO of the company.

Set up by the late Mr. P. P. Singhal, PI started as an edible oil refinery unit and later ventured into the agrochemicals formulation business. In 1978, the company diversified into mining and mineral processing business, which was hived off into a separate company, Wolkem India Ltd. PI also entered the energy metering business in the 1980s, which was also hived off into a separate company, Secure Meters Ltd. To mitigate cyclicality risks in the agrochemicals industry, PI diversified into polymer compounding in the 1990s. Also, in the mid-1990s, PI entered the CRAMS business - currently accounting for  $\sim 35\%$  of the company's revenues. In Apr-11, PI divested the polymer compounding business to French specialty major Rhodia SA for a consideration of  $\sim Rs730m$ .

PI Industries currently operates two formulation and five API facilities under its two business verticals in Jammu and Gujarat. These state-of-art facilities have integrated process development teams and in-house engineering capabilities.

Exhibit 10: Timeline of events



Source: Company, IDFC Securities Research

#### Income statement

Year to 31 Mar (Rs m)	FY09	FY10	FY11	FY12E	FY13E
Net sales	4,629	5,425	7,202	9,183	11,478
% growth	24.8	17.2	32.8	27.5	25.0
Operating expenses	3,984	4,554	5,962	7,530	9,335
EBITDA	645	871	1,241	1,653	2,143
% growth	102.7	35.1	42.4	33.2	29.7
Other income	8	11	7	10	10
Net interest	(222)	(183)	(181)	(211)	(199)
Depreciation	112	129	153	183	215
Pre-tax profit	319	572	913	1,269	1,740
Deferred Tax	33	20	56	-	-
Current Tax	44	135	207	381	522
Profit after tax	242	417	650	888	1,218
Non-recurring items	-	-	-	230	-
Net profit after					
non-recurring items	242	417	650	1,118	1,218
% growth	280.9	72.1	56.0	72.0	8.9

## **Balance** sheet

As on 31 Mar (Rs m)	FY09	FY10	FY11	FY12E	FY13E
Paid-up capital	35	71	112	125	125
Preference share capital	-	206	81	-	-
Reserves & surplus	903	1,269	1,944	2,973	4,094
Total shareholders' equity	939	1,340	2,056	3,098	4,219
Total current liabilities	950	1,191	1,568	2,516	3,145
Total Debt	2,032	1,704	2,559	2,210	2,210
Deferred tax liabilities	250	270	326	300	300
Other non-current liabilities	23	52	134	234	234
Total liabilities	3,255	3,217	4,587	5,260	5,889
Total equity & liabilities	4,194	4,556	6,643	8,358	10,108
Net fixed assets	1,866	2,088	2,876	3,593	3,878
Investments	4	5	5	20	20
Total current assets	2,325	2,464	3,762	4,745	6,209
Working capital	1,374	1,272	2,195	2,230	3,065
Total assets	4,194	4,556	6,643	8,358	10,108

# Cash flow statement

Year to 31 Mar (Rs m)	FY09	FY10	FY11	FY12E	FY13E
Pre-tax profit	319	572	913	1,269	1,740
Depreciation	112	129	153	183	215
Chg in Working capital	(315)	105	(893)	(28)	(377)
Total tax paid	(44)	(135)	(207)	(381)	(522)
Ext ord. Items & others	23	29	83	100	-
Operating cash Inflow	95	699	49	1,143	1,055
Capital expenditure	(332)	(350)	(941)	(900)	(500)
Free cash flow (a+b)	(237)	349	(892)	243	555
Chg in investments	(1)	(38)	75	189	-
Debt raised/(repaid)	257	(535)	981	(268)	-
Capital raised/(repaid)	-	241	(84)	(68)	-
Dividend (incl. tax)	-	(15)	(50)	(89)	(97)
Net chg in cash	20	3	30	7	458


# **Key ratios**

Year to 31 Mar	FY09	FY10	FY11	FY12E	FY13E
EBITDA margin (%)	13.9	16.1	17.2	18.0	18.7
EBIT margin (%)	11.5	13.7	15.1	16.0	16.8
PAT margin (%)	5.2	7.7	9.0	9.7	10.6
RoE (%)	29.5	36.6	38.3	34.5	33.3
RoCE (%)	17.9	22.5	25.8	26.9	30.1
Gearing (x)	2.1	1.2	1.2	0.7	0.4

## **Valuations**

Year to 31 Mar	FY09	FY10	FY11	FY12E	FY13E
Reported EPS (Rs)	17.1	19.3	29.3	44.7	48.7
Adj. EPS (Rs)	17.1	19.3	29.3	35.5	48.7
PER (x)	28.1	24.9	16.4	13.5	9.9
Price/Book (x)	7.2	7.8	5.2	3.9	2.8
EV/Net sales (x)	1.9	2.2	1.8	1.5	1.2
EV/EBITDA (x)	13.6	13.8	10.6	8.5	6.4
EV/CE (x)	2.7	3.6	2.6	2.4	2.0

# Shareholding pattern



As of September 2011

Analyst	Sector/Industry/Coverage	E-mail	Tel.+91-22-6622 2600
Pathik Gandotra	Head of Equities; Financials	pathik.gandotra@idfc.com	91-22-662 22525
Shirish Rane	Co-Head of Research; Construction, Power, Cement	shirish.rane@idfc.com	91-22-662 22575
Nikhil Vora	Co-Head of Research; Strategy, FMCG, Media, Education, Exchanges, Mid Caps	nikhil.vora@idfc.com	91-22-662 22567
Nitin Agarwal	Pharmaceuticals, Real Estate, Agri-inputs	nitin.agarwal@idfc.com	91-22-662 22568
Bhoomika Nair	Logistics, Engineering	bhoomika.nair@idfc.com	91-22-662 22561
Hitesh Shah, CFA	IT Services	hitesh.shah@idfc.com	91-22-662 22565
Bhushan Gajaria	Automobiles, Auto ancillaries, Retailing	bhushan.gajaria@idfc.com	91-22-662 22562
Salil Desai	Construction, Power, Cement	salil.desai@idfc.com	91-22-662 22573
Ashish Shah	Construction, Power, Cement	ashish.shah@idfc.com	91-22-662 22560
Probal Sen	Oil & Gas	probal.sen@idfc.com	91-22-662 22569
Chinmaya Garg	Financials	chinmaya.garg@idfc.com	91-22-662 22563
Abhishek Gupta	Telecom, Metals & Mining	abhishek.gupta@idfc.com	91-22-662 22661
Saumil Mehta	Metals, Pipes	saumil.mehta@idfc.com	91-22-662 22578
Vineet Chandak	Real Estate, Pharmaceuticals, Agri-inputs	vineet.chandak@idfc.com	91-22-662 22579
Anamika Sharma	IT Services	anamika.sharma@idfc.com	91-22-662 22680
Varun Kejriwal	FMCG, Mid Caps, Shipping, Aviation	varun.kejriwal@idfc.com	91-22-662 22685
Swati Nangalia	Media, Education, Exchanges, Midcaps	swati.nangalia@idfc.com	91-22-662 22576
Nikhil Salvi	Construction, Power, Cement	nikhil.salvi@idfc.com	91-22-662 22566
Kavitha Rajan	Strategy, Financials	kavitha.rajan@idfc.com	91-22-662 22697
Dharmendra Sahu	Database Analyst	dharmendra.sahu@idfc.com	91-22-662 22580
Rupesh Sonawale	Database Analyst	rupesh.sonawale@idfc.com	91-22-662 22572
Dharmesh R Bhatt, CMT	Technical Analyst	dharmesh.bhatt@idfc.com	91-22-662 22534
Equity Sales/Dealing	Designation	E-mail	Tel. +91-22-6622 2500
Naishadh Paleja	Co-Group CEO	naishadh.paleja@idfc.com	91-22-6622 2522
Paresh Shah	MD, Dealing	paresh.shah@idfc.com	91-22-6622 2508
Vishal Purohit	MD, Co-Head of Sales	vishal.purohit@idfc.com	91-22-6622 2533
Rajesh Makharia	Director, Sales	rajesh.makharia@idfc.com	91-22-6622 2528
Kalpesh Parekh	Director, Sales	kalpesh.parekh@idfc.com	91-22-6622 2696
Pradip Seth	SVP, Sales	pradip.seth@idfc.com	91-22-6622 2595
Varun Saboo	AVP, Sales	varun.saboo@idfc.com	91-22-6622 2558
Pawan Sharma	MD, Derivatives	pawan.sharma@idfc.com	91-22-6622 2539
Dipesh Shah	Director, Derivatives	dipesh.shah@idfc.com	91-22-6622 2693
Jignesh Shah	AVP, Derivatives	jignesh.shah@idfc.com	91-22-6622 2536
Suniil Pandit	Director, Sales trading	suniil.pandit@idfc.com	91-22-6622 2524
Mukesh Chaturvedi	SVP, Sales trading	mukesh.chaturvedi@idfc.com	
Viren Sompura	SVP, Sales trading	viren.sompura@idfc.com	91-22-6622 2527
Rajashekhar Hiremath	VP, Sales trading	rajashekhar.hiremath@idfc.co	
IDFC Securities US	Designation	E-mail	Telephone
Nikhil Gholani	Chief Executive Officer	nikhil.gholani@idfc.com	001 212 829 4351
Sanjay Panicker	Director	sanjay.panicker@idfc.com	001 212 829 4353

#### Disclaimer

This document has been prepared by IDFC Securities Ltd (IDFC SEC). IDFC SEC and its subsidiaries and associated companies are a full-service, integrated investment banking, investment management and brokerage group. Our research analysts and sales persons provide important input into our investment banking activities

This document does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction.

The information contained herein is from publicly available data or other sources believed to be reliable. While we would endeavor to update the information herein on reasonable basis, the opinions and information in this report are subject to change without notice and IDFC SEC, its subsidiaries and associated companies, their directors and employees (\*IDFC SEC and affiliates\*) are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent IDFC SEC and affiliates from doing so. Thus, the opinions expressed herein should be considered those of IDFC SEC as of the date on this document only. We do not make any representation either express or implied that information contained herein is accurate or complete and it should not be relied upon as such.

The information contained in this document has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed in the document may not be suitable for all investors. Investors should make their own investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and investment decisions based upon their own financial objectives and financial resources. Investors assume the entire risk of any use made of the information contained in the document. Investments in general involve some degree of risk, including the risk of capital loss. Past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested

Foreign currency-denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or the price of, or income derived from, the investment. In addition, investors in securities, the values of which are influenced by foreign currencies, effectively assume currency risk.

Affiliates of IDFC SEC may have issued other reports that are inconsistent with and reach different conclusions from, the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IDFC SEC and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this document may come are required to inform themselves of, and to observe, such applicable restrictions.

Reports based on technical analysis centers on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals.

IDFC SEC and affiliates, their directors, officers, and employees may from time to time have positions in, purchase or sell, or be materially interested in any of the securities mentioned or related securities. IDFC SEC and affiliates may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall IDFC SEC, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind including but not limited to any direct or consequential loss or damage, however arising, from the use of this document. Any comments or statements made herein are those of the analyst and do not necessarily reflect those of IDFC SEC and affiliates.

This document is subject to changes without prior notice and is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material and is not for any type of circulation. Any review, retransmission, or any other use is prohibited.

Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. IDFC SEC will not treat recipients as customers by virtue of their receiving this

IDFC Capital (USA) Inc. has reviewed the report and, to the extent that it includes present or past information, it is believed to be reliable, although its correctness cannot be assured

#### Additional Disclosures of Interest:

- 1. IDFC SEC and its affiliates (i) may have received compensation from the company covered herein in the past twelve months for investment banking services; or (ii) may expect to receive or intends to seek compensation for investment-banking services from the subject company in the next three months from publication of the research report.

  Affiliates of IDFC SEC may have may have managed or co-managed in the previous twelve months a private or public offering of securities for the subject company.
- 3. IDFC SEC and affiliates collectively do not hold more than 1% of the equity of the company that is the subject of the report as of the end of the month preceding the distribution of the research report.

  4. IDFC SEC and affiliates are not acting as a market maker in the securities of the subject company.

#### Explanation of Ratings:

Outperformer More than 5% to Index

Neutral Within 0-5% (upside or downside) to Index

3. Underperformer

**IDFC Securities** Naman Chambers, C-32, 7th floor, G- Block, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051 INDIA Tel: 91-22-6622 2600

Fax: 91-22-6622 2501

Our research is also available on Bloomberg and Thomson Reuters